Evidence map›Paper›PMID 34117631›Full record

ArticlePharmacological reports : PR2021

Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.

Sylwia Szeląg-Pieniek, Stefan Oswald, Mariola Post, Joanna Łapczuk-Romańska, Marek Droździk, Mateusz Kurzawski

Open access · hybridAbstract read
In one paragraph

Article in Pharmacological reports : PR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. The Impact ofGenes · 2026
    Article
  2. Article
  3. Article
  4. Obesity-related drug-metabolizing enzyme expression alterations in the human liver.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sylwia Szeląg-PieniekDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Stefan OswaldInstitute of Pharmacology and Toxicology, Rostock University Medical Center, 18051, Rostock, Germany.
Mariola PostDepartment of General and Transplantation Surgery, Marie Curie Hospital, Arkońska 4, 71-455, Szczecin, Poland.
Joanna Łapczuk-RomańskaDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Marek DroździkDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland. marek.drozdzik@pum.edu.pl.ORCID http://orcid.org/0000-0002-6191-7168
Mateusz KurzawskiDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Pomeranian Medical University · PLUniversity of Rostock · DE

Funding

Minister of Science and Higher Education under the name "Regional Initiative of Excellence" in 2019-2022 002 / RID / 2018/19
6 · The paper itself

Abstract

backgroundWilson's disease is a genetic disorder inherited in a recessive manner, caused by mutations in the copper-transporter ATP7B. Although it is a well-known disease, currently available treatments are far from satisfactory and their efficacy varies in individual patients. Due to the lack of information about drug-metabolizing enzymes and drug transporters profile in Wilson's disease livers, we aimed to evaluate the mRNA expression and protein abundance of selected enzymes and drug transporters in this liver disorder.

methodsWe analyzed gene expression (qPCR) and protein abundance (LC-MS/MS) of 14 drug-metabolizing enzymes and 16 drug transporters in hepatic tissue from Wilson's disease patients with liver failure (n = 7, Child-Pugh class B and C) and metastatic control livers (n = 20).

resultsIn presented work, we demonstrated a downregulation of majority of CYP450 and UGT enzymes. Gene expression of analyzed enzymes ranged between 18 and 65% compared to control group and significantly lower protein content of CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 enzymes was observed in Wilson's disease. Moreover, a general decrease in hepatocellular uptake carriers from SLC superfamily (significant at protein level for NTCP and OATP2B1) was observed. As for ABC transporters, the protein abundance of BSEP and MRP2 was significantly lower, while levels of P-gp and MRP4 transporters were significantly higher in Wilson's disease.

conclusionsAltered hepatic expression of drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure may result in changes of drug pharmacokinetics in that group of patients.

Indexed as

AdultAgedCarrier ProteinsCytochrome P-450 Enzyme SystemDown-RegulationFemaleHepatolenticular DegenerationHumansLiverLiver FailureMaleMiddle AgedPharmaceutical PreparationsRNA, MessengerYoung AdultCarrier ProteinsCytochrome P-450 Enzyme SystemPharmaceutical PreparationsRNA, MessengerCYP450 enzymesDrug transportersLiverProtein abundanceWilson’s disease

Identifiers

PMID34117631
PMCPMC8460590
OpenAlexW3171168561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.